Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

An Exploratory Study of High-dose Glivec in Patients With CML-CP Using Molecular Endpoints

This study is enrolling participants by invitation only.
Sponsor:
Information provided by:
Novartis Korea Ltd.
ClinicalTrials.gov Identifier:
NCT01216085
First received: September 27, 2010
Last updated: October 5, 2010
Last verified: October 2010
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is enrolling participants by invitation only.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)